The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 13, 2024

Filed:

Feb. 08, 2021
Applicant:

University of South Florida, Tampa, FL (US);

Inventors:

Jung A. Woo, Wesley Chapel, FL (US);

Stephen Bryant Liggett, Treasure Island, FL (US);

David E. Kang, Wesley Chapel, FL (US);

Yu Chen, Tampa, FL (US);

Eric Lewandowski, Tampa, FL (US);

Assignee:

UNIVERSITY OF SOUTH FLORIDA, Tampa, FL (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61P 25/28 (2006.01); A61K 31/42 (2006.01); A61K 31/437 (2006.01); A61K 31/496 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1709 (2013.01); A61K 31/42 (2013.01); A61K 31/437 (2013.01); A61K 31/496 (2013.01); A61P 25/28 (2018.01);
Abstract

As disclosed herein, β-arrestin1 and β-arrestin2 levels are highly elevated in brains of FTLD-tau patients suggesting that both β-arrestin1 and β-arrestin2 are elevated in the brains of patients with AD and FLTD. The current work also shows that when β-arrestin2 is overexpressed, tau levels become elevated. The data indicate that β-arrestin2 reduces tau clearance by impairing p62-mediated autophagy, a role carried out by the oligomerized form of β-arrestin2. Therefore, disclosed herein are β-arrestin oligomerization inhibitors that can be used to prevent β-arrestin oligomerization and therefore the accumulation of tau in cells, i.e. tauopathy. Also disclosed are methods of treating a tauopathy in a subject that involve administering to the subject a therapeutically effective amount of a β-arrestin oligomerization inhibitor disclosed herein.


Find Patent Forward Citations

Loading…